source
- Durvalumab plus enfortumab vedotin improves survival outcomes in muscle-invasive bladder cancerA recent clinical study evaluated the perioperative use of durvalumab together with enfortumab vedotin in patients with muscle-invasive bladder cancer. The topline results indicated that the combi…
- Regenxbio reports key gene therapy results, moves toward FDA accelerated clearance for DuchenneRegenxbio said its experimental gene therapy RGX-202 met the primary endpoint in a pivotal Duchenne muscular dystrophy trial, positioning the company to file for accelerated FDA clearance. In the…